Arbutus Biopharma Corp Revenue
Arbutus Biopharma Corp (ABUS) reported Revenue of $1.01 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement
us-gaap:Revenues · last filed 2026-08-12
CAD
| Period end | Revenues 12 month |
|---|---|
| 2012-12-31 | 14.11M CAD 20-F · filed 2013-03-27 |
| 2011-12-31 | 16.65M CAD 20-F · filed 2013-03-27 |
| 2010-12-31 | 21.35M CAD 20-F · filed 2013-03-27 |
| 2009-12-31 | 14.43M CAD 20-F · filed 2012-03-27 |
USD
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 9 month as first filed | Revenues 12 month | Revenues 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.01M 10-Q · filed 2026-08-12 | $180.14M 10-Q · filed 2026-08-12 | $181.19M derived: sum of 3 quarters · filed 2026-08-12 | $181.72M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2026-03-31 | $179.13M 10-Q · filed 2026-05-13 | $180.18M derived: sum of 2 quarters · filed 2026-05-13 | $180.71M derived: sum of 3 quarters · filed 2026-05-13 | $191.44M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.58M derived: sum of 2 quarters · filed 2026-03-23 | $12.32M derived: sum of 3 quarters · filed 2026-08-12 | $14.08M 10-K · filed 2026-03-23 | ||
| 2025-09-30 | $529.00K 10-Q · filed 2025-11-13 | $11.27M derived: sum of 2 quarters · filed 2026-08-12 | $13.03M 10-Q · filed 2025-11-13 | $14.61M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-06-30 | $10.74M 10-Q · filed 2026-08-12 | $12.50M 10-Q · filed 2026-08-12 | $14.08M derived: sum of 3 quarters · filed 2026-08-12 | $15.42M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $1.76M 10-Q · filed 2026-05-13 | $3.34M derived: sum of 2 quarters · filed 2026-05-13 | $4.68M derived: sum of 3 quarters · filed 2026-05-13 | $6.40M derived: sum of 4 quarters · filed 2026-05-13 | ||
| 2024-12-31 | $1.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $2.91M derived: sum of 2 quarters · filed 2026-03-23 | $4.64M derived: sum of 3 quarters · filed 2026-03-23 | $6.17M 10-K · filed 2026-03-23 | ||
| 2024-09-30 | $1.34M 10-Q · filed 2025-11-13 | $3.06M derived: sum of 2 quarters · filed 2025-11-13 | $4.60M 10-Q · filed 2025-11-13 | $6.74M derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $1.73M 10-Q · filed 2025-08-06 | $3.26M 10-Q · filed 2025-08-06 | $5.40M derived: sum of 3 quarters · filed 2025-08-06 | $10.06M derived: sum of 4 quarters · filed 2025-08-06 | ||
| 2024-03-31 | $1.53M 10-Q · filed 2025-05-14 | $3.68M derived: sum of 2 quarters · filed 2025-05-14 | $8.34M derived: sum of 3 quarters · filed 2025-05-14 | $12.99M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $6.80M derived: sum of 2 quarters · filed 2025-03-27 | $11.45M derived: sum of 3 quarters · filed 2025-03-27 | $18.14M 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $4.66M 10-Q · filed 2024-11-06 | $9.31M derived: sum of 2 quarters · filed 2024-11-06 | $16.00M 10-Q · filed 2024-11-06 | $22.24M derived: sum of 4 quarters · filed 2024-11-06 | ||
| 2023-06-30 | $4.65M 10-Q · filed 2024-08-08 | $11.34M 10-Q · filed 2024-08-08 | $17.58M derived: sum of 3 quarters · filed 2024-08-08 | $23.54M derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | $6.69M 10-Q · filed 2024-05-02 | $12.93M derived: sum of 2 quarters · filed 2024-05-02 | $18.88M derived: sum of 3 quarters · filed 2024-05-02 | $33.13M derived: sum of 4 quarters · filed 2024-05-02 | ||
| 2022-12-31 | $6.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $12.20M derived: sum of 2 quarters · filed 2024-03-05 | $26.44M derived: sum of 3 quarters · filed 2024-03-05 | $39.02M 10-K · filed 2024-03-05 | ||
| 2022-09-30 | $5.95M 10-Q · filed 2023-11-07 | $20.19M derived: sum of 2 quarters · filed 2023-11-07 | $32.77M 10-Q · filed 2023-11-07 | $35.98M derived: sum of 4 quarters · filed 2023-11-07 | ||
| 2022-06-30 | $14.24M 10-Q · filed 2023-08-03 | $26.82M 10-Q · filed 2023-08-03 | $30.03M derived: sum of 3 quarters · filed 2023-08-03 | $33.37M derived: sum of 4 quarters · filed 2023-08-03 | ||
| 2022-03-31 | $12.58M 10-Q · filed 2023-05-04 | $15.79M derived: sum of 2 quarters · filed 2023-05-04 | $19.13M derived: sum of 3 quarters · filed 2023-05-04 | $21.46M derived: sum of 4 quarters · filed 2023-05-04 | ||
| 2021-12-31 | $3.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $6.55M derived: sum of 2 quarters · filed 2023-03-02 | $8.88M derived: sum of 3 quarters · filed 2023-03-02 | $10.99M 10-K · filed 2023-03-02 | ||
| 2021-09-30 | $3.34M 10-Q · filed 2022-11-09 | $5.67M derived: sum of 2 quarters · filed 2022-11-09 | $7.78M 10-Q · filed 2022-11-09 | $10.17M derived: sum of 4 quarters · filed 2022-11-09 | ||
| 2021-06-30 | $2.33M 10-Q · filed 2022-08-04 | $4.44M 10-Q · filed 2022-08-04 | $6.83M derived: sum of 3 quarters · filed 2022-08-04 | $8.35M derived: sum of 4 quarters · filed 2022-08-04 | ||
| 2021-03-31 | $2.11M 10-Q · filed 2022-05-05 | $4.50M derived: sum of 2 quarters · filed 2022-05-05 | $6.02M derived: sum of 3 quarters · filed 2022-05-05 | $7.54M derived: sum of 4 quarters · filed 2022-05-05 | ||
| 2020-12-31 | $2.39M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $3.91M derived: sum of 2 quarters · filed 2022-03-03 | $5.42M derived: sum of 3 quarters · filed 2022-03-03 | $6.91M 10-K · filed 2022-03-03 | ||
| 2020-09-30 | $1.52M 10-Q · filed 2021-11-04 | $3.04M derived: sum of 2 quarters · filed 2021-11-04 | $4.53M 10-Q · filed 2021-11-04 | $6.15M derived: sum of 4 quarters · filed 2021-11-04 | ||
| 2020-06-30 | $1.51M 10-Q · filed 2021-08-05 | $3.00M 10-Q · filed 2021-08-05 | $4.62M derived: sum of 3 quarters · filed 2021-08-05 | $7.68M derived: sum of 4 quarters · filed 2021-08-05 | ||
| 2020-03-31 | $1.49M 10-Q · filed 2021-05-05 | $3.11M derived: sum of 2 quarters · filed 2021-05-05 | $6.17M derived: sum of 3 quarters · filed 2021-05-05 | $6.82M derived: sum of 4 quarters · filed 2021-05-05 | ||
| 2019-12-31 | $1.62M 10-K · filed 2020-03-05 | $4.68M derived: sum of 2 quarters · filed 2020-11-05 | $5.33M derived: sum of 3 quarters · filed 2020-11-05 | $6.01M 10-K · filed 2021-03-04 | ||
| 2019-09-30 | $3.06M 10-Q · filed 2020-11-05 | $3.71M derived: sum of 2 quarters · filed 2020-11-05 | $4.39M 10-Q · filed 2020-11-05 | $6.07M derived: sum of 4 quarters · filed 2020-11-05 | ||
| 2019-06-30 | $653.00K 10-Q · filed 2020-08-07 | $1.33M 10-Q · filed 2020-08-07 | $3.01M derived: sum of 3 quarters · filed 2020-08-07 | $4.60M derived: sum of 4 quarters · filed 2020-08-07 | ||
| 2019-03-31 | $679.00K 10-Q · filed 2020-05-11 | $2.36M derived: sum of 2 quarters · filed 2020-05-11 | $3.94M derived: sum of 3 quarters · filed 2020-05-11 | $5.19M derived: sum of 4 quarters · filed 2020-05-11 | ||
| 2018-12-31 | $1.68M 10-K · filed 2020-03-05 | $3.27M derived: sum of 2 quarters · filed 2020-03-05 | $4.51M derived: sum of 3 quarters · filed 2020-03-05 | $5.95M 10-K · filed 2020-03-05 | ||
| 2018-09-30 | $1.59M 10-Q · filed 2019-11-06 | $2.83M derived: sum of 2 quarters · filed 2020-03-05 | $1.59M 10-K · filed 2020-03-05 | $4.27M 10-Q · filed 2018-11-07 | $6.80M derived: sum of 4 quarters · filed 2020-03-05 | |
| 2018-06-30 | $1.24M 10-K · filed 2020-03-05 | $2.68M 10-Q · filed 2019-08-05 | $5.21M derived: sum of 3 quarters · filed 2020-03-05 | $12.11M derived: sum of 4 quarters · filed 2020-03-05 | ||
| 2018-03-31 | $1.44M 10-K · filed 2020-03-05 | $3.97M derived: sum of 2 quarters · filed 2020-03-05 | $10.86M derived: sum of 3 quarters · filed 2020-03-05 | $11.90M derived: sum of 4 quarters · filed 2020-03-05 | ||
| 2017-12-31 | $2.53M 10-K · filed 2019-03-07 | $9.43M derived: sum of 2 quarters · filed 2019-03-07 | $10.46M derived: sum of 3 quarters · filed 2019-03-07 | $10.70M 10-K · filed 2019-03-07 | ||
| 2017-09-30 | $6.89M 10-K · filed 2019-03-07 | $7.93M derived: sum of 2 quarters · filed 2019-03-07 | $8.17M 10-Q · filed 2018-11-07 | $7.97M derived: sum of 4 quarters · filed 2019-03-07 | ||
| 2017-06-30 | $1.04M 10-K · filed 2019-03-07 | $1.27M 10-Q · filed 2018-08-03 | $1.08M derived: sum of 3 quarters · filed 2019-03-07 | $1.85M derived: sum of 4 quarters · filed 2019-03-07 | ||
| 2017-03-31 | $235.00K 10-K · filed 2019-03-07 | $40.00K derived: sum of 2 quarters · filed 2019-03-07 | $814.00K derived: sum of 3 quarters · filed 2019-03-07 | $1.12M derived: sum of 4 quarters · filed 2019-03-07 | ||
| 2016-12-31 | -$195.00K 10-K · filed 2018-03-16 | $579.00K derived: sum of 2 quarters · filed 2018-03-16 | $888.00K derived: sum of 3 quarters · filed 2018-03-16 | $1.49M 10-K · filed 2018-03-16 | ||
| 2016-09-30 | $774.00K 10-K · filed 2018-03-16 | $1.08M derived: sum of 2 quarters · filed 2018-03-16 | $1.69M 10-Q · filed 2017-11-02 | $14.37M derived: sum of 4 quarters · filed 2018-03-16 | ||
| 2016-06-30 | $309.00K 10-K · filed 2018-03-16 | $912.00K 10-Q · filed 2017-08-03 | $13.60M derived: sum of 3 quarters · filed 2018-03-16 | $17.66M derived: sum of 4 quarters · filed 2018-03-16 | ||
| 2016-03-31 | $603.00K 10-K · filed 2018-03-16 | $13.29M derived: sum of 2 quarters · filed 2018-03-16 | $17.35M derived: sum of 3 quarters · filed 2018-03-16 | $20.79M derived: sum of 4 quarters · filed 2018-03-16 | ||
| 2015-12-31 | $12.69M 10-K · filed 2017-03-22 | $16.75M derived: sum of 2 quarters · filed 2017-03-22 | $20.19M derived: sum of 3 quarters · filed 2017-03-22 | $23.28M 10-K · filed 2018-03-16 | $24.87M 10-K · filed 2016-03-09 | |
| 2015-09-30 | $4.07M 10-K · filed 2017-03-22 | $4.07M 10-Q · filed 2015-11-05 | $12.19M 10-Q · filed 2016-11-03 | $16.54M derived: sum of 4 quarters · filed 2017-03-22 | ||
| 2015-06-30 | $3.44M 10-K · filed 2017-03-22 | $8.12M 10-Q · filed 2016-08-04 | $12.47M derived: sum of 3 quarters · filed 2017-03-22 | $16.83M derived: sum of 4 quarters · filed 2017-03-22 | ||
| 2015-03-31 | $4.68M 10-K · filed 2017-03-22 | $9.03M derived: sum of 2 quarters · filed 2017-03-22 | $13.39M derived: sum of 3 quarters · filed 2017-03-22 | $15.21M derived: sum of 4 quarters · filed 2017-03-22 | ||
| 2014-12-31 | $4.35M 10-K · filed 2016-03-09 | $8.71M derived: sum of 2 quarters · filed 2016-03-09 | $10.52M derived: sum of 3 quarters · filed 2016-03-09 | $14.95M 10-K · filed 2017-03-22 | ||
| 2014-09-30 | $4.36M 10-K · filed 2016-03-09 | $4.36M 10-Q · filed 2015-11-05 | $10.60M 10-Q · filed 2015-11-05 | $11.36M derived: sum of 4 quarters · filed 2016-03-09 | ||
| 2014-06-30 | $1.81M 10-K · filed 2016-03-09 | $6.24M 10-Q · filed 2015-08-07 | $6.99M derived: sum of 3 quarters · filed 2016-03-09 | $9.96M derived: sum of 4 quarters · filed 2016-03-09 | ||
| 2014-03-31 | $4.43M 10-K · filed 2016-03-09 | $5.18M derived: sum of 2 quarters · filed 2016-03-09 | $8.14M derived: sum of 3 quarters · filed 2016-03-09 | $10.99M derived: sum of 4 quarters · filed 2016-03-09 | ||
| 2013-12-31 | $752.00K 10-K · filed 2015-03-13 | $3.71M derived: sum of 2 quarters · filed 2015-03-13 | $6.56M derived: sum of 3 quarters · filed 2015-03-13 | $15.46M 10-K · filed 2016-03-09 | $15.46M 6-K · filed 2014-03-06 | |
| 2013-09-30 | $2.96M 10-K · filed 2015-03-13 | $5.81M derived: sum of 2 quarters · filed 2015-03-13 | $7.94M 10-Q · filed 2014-11-07 | |||
| 2013-06-30 | $2.84M 10-K · filed 2015-03-13 | $4.97M 10-Q · filed 2014-08-14 | ||||
| 2013-03-31 | $2.13M 10-K · filed 2015-03-13 | |||||
| 2012-12-31 | $14.11M 10-K · filed 2015-03-13 | $14.11M 6-K · filed 2014-03-06 | ||||
| 2011-12-31 | $16.81M 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |